Giverny Capital Inc. Sells 2,150 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Giverny Capital trimmed its Medpace stake by 0.8%, selling 2,150 shares while retaining 253,931 shares valued at approximately $134.5 million. Institutional investors collectively own about 78% of the company.
• Analyst sentiment remains mixed: Medpace has an average rating of “Hold” and a consensus price target of $595.20, although several firms recently raised their targets and maintained or issued outperform ratings.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 and revenue of $707.3 million, while revenue increased 17.2% year over year. However, insiders sold 134,471 shares worth approximately $82.2 million during the quarter.

Giverny Capital Inc. cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 0.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,931 shares of the company's stock after selling 2,150 shares during the period. Medpace comprises approximately 4.6% of Giverny Capital Inc.'s portfolio, making the stock its 7th largest position. Giverny Capital Inc. owned approximately 0.91% of Medpace worth $134,479,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. California State Teachers Retirement System increased its position in shares of Medpace by 53,619.6% during the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company's stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC boosted its position in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company's stock valued at $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP grew its stake in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after buying an additional 24,625 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Finally, Robert W. Baird increased their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, Medpace has an average rating of "Hold" and a consensus price target of $595.20.

Insider Activity

In related news, Director Brian Carley sold 5,000 shares of Medpace stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the transaction, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. This trade represents a 15.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert Kraft sold 3,858 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the completion of the transaction, the director directly owned 955 shares in the company, valued at $590,008.55. This represents a 80.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is currently owned by company insiders.

Medpace Price Performance

MEDP opened at $591.29 on Monday. The business has a 50 day moving average price of $574.67 and a two-hundred day moving average price of $500.02. The company has a market cap of $16.50 billion, a PE ratio of 34.66, a P/E/G ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.